Last updated: April 23, 2026
Who Supplies Oxymetazoline Hydrochloride (API and Finished Dosage Forms)?
Oxymetazoline hydrochloride is a widely used nasal decongestant active pharmaceutical ingredient (API) with a long commercial supply chain. Publicly accessible vendor listings commonly split sourcing into (1) API manufacturers (including generic API producers) and (2) finished-dose manufacturers for nasal sprays/drops that use oxymetazoline HCl.
What are the typical supplier categories for oxymetazoline hydrochloride?
| Supplier category |
What they provide |
Typical procurement use |
| API manufacturers |
Oxymetazoline hydrochloride (bulk drug substance), often with DMF/CoA support where applicable |
Contract API supply for generics/brand relabelers |
| Toll/API processing networks |
Routes for crystallization, conversion to salt form, finishing specs, packaging |
Outsourced supply continuity or scale-up |
| Finished-dose manufacturers |
Nasal sprays/drops containing oxymetazoline HCl (often under private label) |
Brand building, channel exclusivity, regulatory package submission |
| Regional distributors/traders |
Lot aggregation and logistics from API or finished-dose makers |
Short-cycle sourcing, multi-lot availability |
Which supplier companies are commonly listed for oxymetazoline hydrochloride?
Public supplier discovery for oxymetazoline hydrochloride is typically driven by vendor databases (chemical catalog listings) and generic supply directories. Those listings often name companies that sell either API or finished product. Commonly referenced supplier names include:
- Zhejiang NHU Co., Ltd. (API and pharmaceutical ingredients supply footprint across China and global markets)
- Hubei Qianjiang Pharmaceutical Co., Ltd. (API supply presence in generic ingredient catalogs)
- Ningbo Sansheng Chemical Co., Ltd. (bulk chemical/API listings for oxymetazoline HCl)
- Tianjin Chase Sun Pharmaceutical Co., Ltd. (regional generic API supply presence)
- Shanghai Uqun Pharmaceutical Co., Ltd. (API/fine chemical supplier listings)
- Aurobindo Pharma (finished generic footprint in decongestants; oxymetazoline products in multiple markets)
- Teva Pharmaceutical Industries (finished generic nasal decongestant footprint where formulations include oxymetazoline)
- Hikma Pharmaceuticals (finished-dose generic footprint in select markets for nasal decongestants)
Important procurement point: supplier visibility for oxymetazoline hydrochloride often changes by jurisdiction because finished-dose availability and regulatory approvals are country-specific, while API vendors vary by approved DMF status and quality system certification. For investment or R&D sourcing, the binding selection criteria usually land on DMF availability, CoA history, cGMP status, and verified stability/traceability for your intended grade.
What grades/specs do suppliers typically quote for oxymetazoline HCl?
Oxymetazoline hydrochloride listings and regulatory dossiers typically map to these common spec buckets:
- Assay/potency: typically high purity with a specified active content range (vendor-dependent)
- Impurities: related substances and solvent residues (ICH-aligned reporting in finished dossier contexts)
- Solubility and physical form: crystalline form and particle-size distribution (often used in formulation performance)
- Moisture/water content: controlled for stability and manufacturability
- Microbial and endotoxin (if API grade for oral/ocular use vs nasal use): nasal API and intermediates often get lower bioburden expectations than sterile products, but suppliers still quote controlled limits depending on the intended use
Which finished-dose supply chains matter for oxymetazoline nasal products?
For nasal sprays and drops, finished-dose suppliers generally differentiate by:
- Container system: pump spray vs dropper bottle vs unit-dose presentation
- Preservative system: multi-dose vs single-dose compliance requirements
- Dosage strength: commonly 0.025% and 0.05% in many markets (product-specific)
- Regulatory package: national registration file and stability protocol acceptance
Finished-dose suppliers are commonly regional in distribution, but multinationals with generic portfolios often support private label or local launches through authorized manufacturing partners.
How to shortlist suppliers for oxymetazoline HCl (API vs finished dose)?
For API shortlisting, procurement teams typically constrain to:
- Confirmed cGMP manufacturing status for API grade relevant to intended filing
- DMF/ASMF status readiness (or letter of access path)
- Audit history and acceptable deviation record
- Consistent impurity profile and batch-to-batch assay range
- Stability support: real-time and accelerated data tied to your target filing strategy
For finished dose sourcing, shortlisting centers on:
- Ability to supply under your brand or private-label specification
- Completed regulatory track record in your target geography
- Container, closure, and labeling capability for the intended market
- Supply continuity and lead times for multi-lot commercial shipments
Where do the biggest supply risks tend to show up?
| Risk point |
How it impacts sourcing |
| DMF/ASMF access friction |
Delays filing timeline or forces alternate suppliers |
| Impurity drift across vendors |
Reformulation or bridging studies may be required |
| Seasonal demand spikes |
Decongestant categories can create procurement bottlenecks |
| Packaging changes for finished doses |
Container/closure modifications can trigger stability updates |
Key Takeaways
- Oxymetazoline hydrochloride sourcing splits into API manufacturers and finished-dose (nasal spray/drop) manufacturers, with vendor lists frequently updated by market approval status.
- Supplier selection should be driven by DMF/ASMF readiness, cGMP status, impurity profile consistency, and stability support for API; and container/closure, regulatory dossier readiness, and private-label capability for finished doses.
- In practice, the most actionable shortlist will come from vendors that can prove batch history, audit acceptance, and stability packages aligned to your target geography.
FAQs
1) Is oxymetazoline hydrochloride sourced more commonly as API or finished product?
Most generics and product developers source as API for formulation, while channel partners and private label brands frequently source finished dose to reduce regulatory and manufacturing overhead.
2) Are oxymetazoline HCl suppliers typically region-specific?
API suppliers often operate across multiple export markets, while finished-dose suppliers are more country-approval-driven, so availability is often region-specific.
3) What is the most important supplier qualification for API filings?
The binding requirement is regulatory documentation readiness (DMF/ASMF or letter-of-access pathway), aligned with cGMP manufacturing and impurity/stability data.
4) Do finished-dose manufacturers change strength/concentration frequently?
Strength and preservative systems vary by country label requirements; procurement teams should lock on exact concentration, container type, and preservative system to avoid reformulation gaps.
5) What tends to cause supply discontinuity for decongestants?
Lead time and capacity shifts can occur around seasonal demand and compounding regulatory or audit findings, creating uneven lot availability.
References
[1] FDA. Drug Approval Reports. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] EMA. European public assessment reports (EPAR). https://www.ema.europa.eu/en/medicines
[3] ICH. ICH Guidelines for stability and impurities (general framework). https://www.ich.org/page/quality-guidelines
[4] USP. Oxymetazoline Hydrochloride monograph and general chapter framework. https://www.uspnf.com/
